A large holder of Valeant’s bonds has called a default as a result of the drugmaker’s failure to file its annual report on time.
WSJ.com: US Business, Wall Street Journal: Business
Tue, 04/12/2016 - 2:39pm
A large holder of Valeant’s bonds has called a default as a result of the drugmaker’s failure to file its annual report on time.